

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A01/2016

DISPATCHED ON 02ND FEBRUARY 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A3; B37, B60; Cw6, Cw10; DR4, DR15; DQ6, DQ8

			Summary of Results								
			PBL/T-Cells				B-Cells				
Total tested			21	21	21	20	20	18	20	19	
Positive			21	0	0	2	20	1	1	9	
Negative			0	21	21	18	0	17	19	10	
NT/Equivocal			0	0	0	1	0	2	0	1	
% Positive			100.0%	0.0%	0.0%	10.0%	100.0%	5.6%	5.0%	47.4%	
% Negative			0.0%	100.0%	100.0%	90.0%	0.0%	94.4%	95.0%	52.6%	
Consensus			Positive	Negative	Negative	Negative	Positive	Negative	Negative	Not Assessed	
HLA Antibody Specificity			Cw4, Cw6	B8,B44,DR5,DR8 DR13	DR17+	B14+	Cw4, Cw6	B8,B44,DR5,DR 8 DR13	DR17+	B14+	
(Defined By CDC)											
Lab No.	PBL/T Cell Assessment	B Cell Assessment	Without DTT				Without DTT				Comments
			Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	YES	YES	Positive	Negative	Negative	Negative	Positive	Equivocal	Negative	Negative	
11	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
12	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	
14	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
15	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
20	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
23	YES	YES	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Positive	
24	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	
25	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
28	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
34	YES	YES	Positive	Negative	Negative	Positive	Positive	Negative	Negative	Positive	
35	YES	NO	Positive	Negative	Negative	Negative					
38	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
39	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
41	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	
42	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
45	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	
51	YES	YES	Positive	Negative	Negative	Equivocal	Positive	Negative	Negative	Equivocal	
54	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
58	YES	YES	Positive	Negative	Negative	Positive	Positive	Equivocal	Negative	Positive	
62	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A01/2016

DISPATCHED ON 02ND FEBRUARY 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A3; B37, B60; Cw6, Cw10; DR4, DR15; DQ6, DQ8

			Summary of Results								
			PBL/T-Cells				B-Cells				
Total tested	21	21	21	20	20	18	20	19			
Positive	21	0	0	2	20	1	1	9			
Negative	0	21	21	18	0	17	19	10			
NT/Equivocal	0	0	0	1	0	2	0	1			
% Positive	100.0%	0.0%	0.0%	10.0%	100.0%	5.6%	5.0%	47.4%			
% Negative	0.0%	100.0%	100.0%	90.0%	0.0%	94.4%	95.0%	52.6%			
Consensus	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Not Assessed			
HLA Antibody Specificity	Cw4, Cw6	B8,B44,DR5,DR8 DR13	DR17+	B14+	Cw4, Cw6	B8,B44,DR5,DR 8 DR13	DR17+	B14+			
(Defined By CDC)											
Lab No.	PBL/T Cell Assessment	B Cell Assessment	Without DTT				Without DTT				Comments
			Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	YES	YES	Positive	Negative	Negative	Negative	Positive	Equivocal	Negative	Negative	
11	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
12	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	
14	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
15	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
20	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
23	YES	YES	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Positive	
24	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	
25	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
28	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
34	YES	YES	Positive	Negative	Negative	Positive	Positive	Negative	Negative	Positive	
35	YES	NO	Positive	Negative	Negative	Negative					
38	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
39	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
41	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	
42	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
45	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	
51	YES	YES	Positive	Negative	Negative	Equivocal	Positive	Negative	Negative	Equivocal	
54	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
58	YES	YES	Positive	Negative	Negative	Positive	Positive	Equivocal	Negative	Positive	
62	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A01/2016

DISPATCHED ON 02ND FEBRUARY 2016

Lab No.	PBL/T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	4	0	0	0	6		0	0		95	90
11	60%				80%				80	80	80
12	4	1	1	1	8	1	1	4	90	90	85
14	8	0	0	0	8	0	2	6		95	95
15	4	0	0	0	2	0	0	0		90	90
20	9	1	1	1	9	1	1	1	90	90	90
23	6	1	1	1	8	4	2	4		90	80
24	100%	10%	10%	20%	100%	30%	30%	40%		90	80
25	6	1	1	1	6	1	1	1		99	99
28	6	1	1	1	8	1	1	1		95	95
34	8	1	1	2	8	1	1	4		99	85
35	6								70	90	
38	8	1	1	1	6	1	1	1	98	95	90
39	2				8				98		98
41	90%				95%			30		90	85
42	80-100%	<10%	<10%	<10%	80-100%	<10%	<10%	<10%	90		75
45	8	1	1	4	8	1	1	4		99	95
51	8	0	0	2	8	0	0	1		95	95
54	60%	0%	0%	10%	80%	0%	0%	20%		>90	>90
58	100%	<5%	<5%	40%	100%	20%	10%	40%		95	90
62	8	1	1	2	8	2	1	4		99	90

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A01/2016

DISPATCHED ON 02ND FEBRUARY 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A3; B37, B60; Cw6, Cw10; DR4, DR15; DQ6, DQ8

			Summary of Results								
			PBL/T-Cells				B-Cells				
Total tested			18	18	18	18	17	16	17	17	
Positive			15	0	0	0	15	0	0	0	
Negative			3	18	18	18	2	16	17	17	
NT/Equivocal			0	0	0	0	0	1	0	0	
% Positive			83.3%	0.0%	0.0%	0.0%	88.2%	0.0%	0.0%	0.0%	
% Negative			16.7%	100.0%	100.0%	100.0%	11.8%	100.0%	100.0%	100.0%	
Consensus			Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
HLA Antibody Specificity			Cw4, Cw6	B8,B44,DR5,DR8 DR13	DR17+	B14+	Cw4, Cw6	B8,B44,DR5,DR8 DR13	DR17+	B14+	
(Defined By CDC)											
Lab No.	PBL/T Cell Assessment	B Cell Assessment	With DTT				With DTT				Comments
			Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	YES	YES	Positive	Negative	Negative	Negative	Positive	Equivocal	Negative	Negative	
11	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
12	YES	YES	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
14	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
15	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
20	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
24	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
25	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
28	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
34	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
35	YES	NO	Positive	Negative	Negative	Negative					
38	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
39	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
41	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
42	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
45	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
51	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
58	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A01/2016

DISPATCHED ON 02ND FEBRUARY 2016

Lab No.	PBL/T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	4	0	0	0	6		0	0		95	90
11	40%				80%				80	80	80
12	2	1	1	1	4	1	1	1	90	90	85
14	4	0	0	0	8	0	0	0		95	95
15	2	0	0	0	2	0	0	0		90	90
20	8	1	1	1	4	1	1	1	90	90	90
24	90%	10%	10%	10%	100%	20%	20%	20%		90	80
25	2	1	1	1	2	1	1	1		99	99
28	4	1	1	1	4	1	1	1		95	95
34	2	1	1	1	8	1	1	1		99	85
35	4								70	90	
38	1	1	1	1	1	1	1	1	98	95	90
39	4				6				98		98
41	95%				95%					90	85
42	80-100%	<10%	<10%	<10%	20-40%	<10%	<10%	<10%	90		75
45	8	1	1	1	8	1	1	1		99	95
51	8	0	0	0	8	0	0	0		95	95
58	100%	<5%	<5%	<5%	100%	<5%	<5%	<5%		95	90